» Articles » PMID: 25356874

Glutathione Depletion Sensitizes Cisplatin- and Temozolomide-resistant Glioma Cells in Vitro and in Vivo

Overview
Journal Cell Death Dis
Date 2014 Oct 31
PMID 25356874
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy. The main chemotherapy protocol for this type of tumor is based on temozolomide (TMZ), albeit with limited success. Cisplatin is widely used to treat several types of tumor and, in association with TMZ, is also used to treat recurrent glioma. However, several mechanisms of cellular resistance to cisplatin restrict therapy efficiency. In that sense, enhanced DNA repair, high glutathione levels and functional p53 have a critical role on cisplatin resistance. In this work, we explored several mechanisms of cisplatin resistance in human glioma. We showed that cellular survival was independent of the p53 status of those cells. In addition, in a host-cell reactivation assay using cisplatin-treated plasmid, we did not detect any difference in DNA repair capacity. We demonstrated that cisplatin-treated U138MG cells suffered fewer DNA double-strand breaks and DNA platination. Interestingly, the resistant cells carried higher levels of intracellular glutathione. Thus, preincubation with the glutathione inhibitor buthionine sulfoximine (BSO) induced massive cell death, whereas N-acetyl cysteine, a precursor of glutathione synthesis, improved the resistance to cisplatin treatment. In addition, BSO sensitized glioma cells to TMZ alone or in combination with cisplatin. Furthermore, using an in vivo model the combination of BSO, cisplatin and TMZ activated the caspase 3-7 apoptotic pathway. Remarkably, the combined treatment did not lead to severe side effects, while causing a huge impact on tumor progression. In fact, we noted a remarkable threefold increase in survival rate compared with other treatment regimens. Thus, the intracellular glutathione concentration is a potential molecular marker for cisplatin resistance in glioma, and the use of glutathione inhibitors, such as BSO, in association with cisplatin and TMZ seems a promising approach for the therapy of such devastating tumors.

Citing Articles

Inhibition of Thioredoxin-Reductase by Auranofin as a Pro-Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies.

Chmelyuk N, Kordyukova M, Sorokina M, Sinyavskiy S, Meshcheryakova V, Belousov V Int J Mol Sci. 2025; 26(5).

PMID: 40076706 PMC: 11900239. DOI: 10.3390/ijms26052084.


Copper-Induced Enhancement of Glioblastoma Tumorigenicity via Cytochrome C Oxidase.

Oliva C, Ali M, Flor S, Griguer C Antioxidants (Basel). 2025; 14(2).

PMID: 40002329 PMC: 11851629. DOI: 10.3390/antiox14020142.


Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration.

Bae W, Maraka S, Daher A Front Oncol. 2024; 14:1441460.

PMID: 39439947 PMC: 11493774. DOI: 10.3389/fonc.2024.1441460.


Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression.

Martinez-Jaramillo E, Jamali F, Abdalbari F, Abdulkarim B, Jean-Claude B, Telleria C Cancers (Basel). 2024; 16(13).

PMID: 39001381 PMC: 11240359. DOI: 10.3390/cancers16132319.


Combinatorial Therapy: Targeting CD133+ Glioma Stem-like Cells with a Polysaccharide-Prodrug Complex Functionalised Gold Nanocages.

Raveendran S, Giram A, Elmi M, Ray S, Ireson C, Alavijeh M Biomedicines. 2024; 12(5).

PMID: 38790896 PMC: 11117750. DOI: 10.3390/biomedicines12050934.


References
1.
Byun S, Kim S, Choi H, Lee C, Lee E . Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int. 2005; 95(7):1086-90. DOI: 10.1111/j.1464-410X.2005.05472.x. View

2.
van den Bent M, Hegi M, Stupp R . Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer. 2006; 42(5):582-8. DOI: 10.1016/j.ejca.2005.06.031. View

3.
van de Vaart P, Belderbos J, de Jong D, Sneeuw K, Majoor D, Bartelink H . DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer. 2001; 89(2):160-6. View

4.
Calvert P, Yao K, Hamilton T, ODwyer P . Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact. 1998; 111-112:213-24. DOI: 10.1016/s0009-2797(98)00008-8. View

5.
Tentori L, Dorio A, Mazzon E, Muzi A, Sau A, Cuzzocrea S . The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. Eur J Cancer. 2011; 47(8):1219-30. DOI: 10.1016/j.ejca.2010.12.008. View